Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA (No number)
Received: 12 November 2018
Accepted: 11 January 2019
First Online: 25 January 2019
Ethics approval and consent to participate
: This survey was a Quality Assurance/Quality Improvement (QA/QI) initiative that was conducted as an anonymized survey with no collection of any Health Insurance Portability and Accountability Act (HIPAA) identifier elements, and therefore it did not require an approval from the Institutional Review Board.
: No individual person’s data were presented in any form in this study and therefore no consent to publish is required.
: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. He owns stock options in Amarin Pharmaceuticals, Inc. He is a member of the Veterans Affairs Rheumatology Field Advisory Committee. He is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. He served as a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee, and the co-chair of the ACR Criteria and Response Criteria subcommittee. He is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.